DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

The global antibody drug conjugate (ADC) market size was valued at USD 13.51 billion in 2025 and is predicted to hit around ...

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

The Company is presenting comparative analyses of pre|CISION ® payload delivery via one of its programs, AVA6103, compared with now two approved Antibody-Drug Conjugates (ADCs).It is also presenting ...

Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity By 2030 With The 1St Approved Bsadc By 2028 - Clinical Trials, Regulatory Approvals, Development Platforms.

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Chemotherapy drugs are well suited to killing cancer cells, but they’re bad at killing only cancer cells — the destruction of healthy tissue has been an inevitable outcome. This toxicity is why ...